Home Newsfeeds Citigroup Maintains Neutral on Agilent Technologies, Raises Price Target to $145

Citigroup Maintains Neutral on Agilent Technologies, Raises Price Target to $145

Citigroup analyst Patrick Donnelly maintains Agilent Technologies (NYSE:A) with a Neutral and raises the price target from $140 to $145.

byBenzinga Newsdesk

August 17, 2022

1 minute read

Citigroup analyst Patrick Donnelly maintains Agilent Technologies (NYSE:A) with a Neutral and raises the price target from $140 to $145.

Atossa Completes Enrollment Of Pharmacokinetic Run-In Cohort In Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen As A Neoadjuvant Treatment For ER+ / HER2- Breast Cancer

By Benzinga Newsdesk

June 12, 9:16 AM

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today

ATOS

Why Is Retail Giant Target Stock Plunging Today?

By Shivani Kumaresan

May 22, 8:00 AM

Target shares fell as first-quarter FY24 adjusted EPS missed estimates. Despite a 3.1% year-on-year sales decline to $24.531 billion, exceeding expectations, comparable sales dropped 3.7%. Target forecasts FY24 adjusted EPS of $8.60 - $9.60 with a 0%-2% rise in comparable sales.

TGT

Over $24M Bet On RXO? Check Out These 3 Stocks Insiders Are Buying

By Avi Kapoor

April 22, 8:57 AM

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. When insiders purchase shares,…

HROW

Why Automotive Seating Company Adient Shares Are Gaining Today

By Akanksha Bakshi

January 22, 10:59 AM

Adient's latest financial numbers provided showcase a remarkable resilience in the face of industry-wide challenges, with a steady revenue projection and a slight increase in Adjusted EBITDA.

ADNT

Citigroup Maintains Neutral on Agilent Technologies, Raises Price Target to $145

Related Posts

Atossa Completes Enrollment Of Pharmacokinetic Run-In Cohort In Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen As A Neoadjuvant Treatment For ER+ / HER2- Breast Cancer

Why Is Retail Giant Target Stock Plunging Today?

Over $24M Bet On RXO? Check Out These 3 Stocks Insiders Are Buying

Why Automotive Seating Company Adient Shares Are Gaining Today